(Total Views: 330)
Posted On: 10/18/2017 11:20:15 AM
Post# of 72446
Trying to determine the effect of the PR will be tough.
B-OM: Top line results very soon, likely in Nov. Had very promising interim results. If interim results are replicated, the Brilacidin platform should be a lock for a solid deal.
Kevetrin Phase 2A: Cohort A readout in Q4 some time. Could demonstrate nothing or could hint at one of the biggest cancer breakthroughs ever.
Prurisol 2B: Top line results likely in the Dec-Jan area. Higher dosage, easier target population and easier grading metrics than phase 2a. Should result in something between a marketable deal candidate to an absolute blockbuster.
Partnership: If the results of B-OM and Prurisol are good, I would expect a partnership in 2018, probably in the first half. If none of the previously mentioned trial results move the shareprice up significantly, a partnership likely will.
Lots of good trial nuggets coming in the next four months. A deal is also likely in the next 6-12 months. I wouldn't worry too much about how this PR impacts things. Just make sure you have your seat at the IPIX table for when the main course is served.
Go IPIX!
B-OM: Top line results very soon, likely in Nov. Had very promising interim results. If interim results are replicated, the Brilacidin platform should be a lock for a solid deal.
Kevetrin Phase 2A: Cohort A readout in Q4 some time. Could demonstrate nothing or could hint at one of the biggest cancer breakthroughs ever.
Prurisol 2B: Top line results likely in the Dec-Jan area. Higher dosage, easier target population and easier grading metrics than phase 2a. Should result in something between a marketable deal candidate to an absolute blockbuster.
Partnership: If the results of B-OM and Prurisol are good, I would expect a partnership in 2018, probably in the first half. If none of the previously mentioned trial results move the shareprice up significantly, a partnership likely will.
Lots of good trial nuggets coming in the next four months. A deal is also likely in the next 6-12 months. I wouldn't worry too much about how this PR impacts things. Just make sure you have your seat at the IPIX table for when the main course is served.
Go IPIX!
(3)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
